

Manuscript Number:

Title: ESTRO ACROP consensus guideline for target volume delineation in the setting of postmastectomy radiation therapy after implant-based immediate reconstruction for early stage breast cancer

Article Type: Full Length Article

Section/Category: Guidelines

Keywords: guideline; target volume delineation; postmastectomy; radiation therapy; reconstruction; early stage breast cancer

Corresponding Author: Ms. Chiara Gasparotto,

Corresponding Author's Institution: ESTRO

First Author: Chiara Gasparotto

Order of Authors: Chiara Gasparotto; Orit Kaidar-Person; Birgitte Vrou Offersen; Sandra Hol; Meritxell Arenas; Cynthia Aristei; Celine Bourgier; Maria Joao Cardoso; Boon Chua; Charlotte Coles; Tine Engberg Damsgaard; Dorota Gabrys; Reshma Jagsi; Rachel Jimenez; Anna M Kirby; Carine Kirkove; Youlia Kirova; Vassilis Kouloulis; Tanja Marinko; Icro Meattini; Ingvil Mjaaland; Gustavo Nader Marta; Petra Witt Nystroem; Elzbieta Senkus; Tanja Skyttä; Tove F Tvedskov; Karolien Verhoeven; Philip Poortmans

Abstract: Immediate breast reconstruction (IBR) rates after mastectomy are increasing. Postmastectomy radiation therapy (PMRT) contouring guidelines for target volumes in the setting of IBR are lacking. Therefore, many patients who have had IBR receive PMRT to target volumes similar to conventional simulator-based whole breast irradiation. The aim of this paper is to describe delineation guidelines for PMRT after implant-based IBR based on a thorough understanding of the surgical procedures, disease stage, patterns of recurrence and radiation techniques. They are based on a consensus endorsed by a global multidisciplinary group of breast cancer experts.

1
2
3
4 **ESTRO ACROP consensus guideline for target volume delineation in the setting of**
5
6
7 **postmastectomy radiation therapy after implant-based immediate reconstruction for early**
8
9 **stage breast cancer**

10
11 Orit Kaidar-Person*, Birgitte Vrou Offersen*, Sandra Hol, Meritxell Arenas, Cynthia Aristei,
12
13
14 Celine Bourgier, Maria Joao Cardoso, Boon Chua, Charlotte Coles, Tine Engberg Damsgaard,
15
16
17 Dorota Gabrys, Reshma Jagsi, Rachel Jimenez, Anna M. Kirby, Carine Kirkove, Youlia Kirova,
18
19
20 Vassilis Kouloulis, Tanja Marinko, Icro Meattini, Ingvil Mjaaland, Gustavo Nader Marta, Petra
21
22
23 Witt Nystroem, Elzbieta Senkus, Tanja Skyttä, Tove F Tvedskov, Karolien Verhoeven, Philip
24
25
26 Poortmans.

27 *Both authors contributed equally.

28
29
30 RUNNING TITLE: Target volumes for PMRT after implant-based breast reconstruction.

31
32
33 KEY WORDS: Breast cancer, radiation therapy, mastectomy, immediate reconstruction, implant,
34
35
36 guidelines

37
38
39
40
41 **Address for correspondence:**

42
43
44 Orit Kaidar-Person, MD

45
46
47 Radiation Oncology Unit, Oncology Institute,

48
49
50 Rambam Medical Center, Haifa, Israel

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Acknowledgments: The authors would like to thank Liesbeth Boersma, Alice Ho, Claus Kamby, Fiona MacNeill, Sofia Rivera, Yvonne Zissiadis and Miika Palmu for their support and assistance with this project.

The authors dedicate these guidelines to all breast cancer patients, past, present and future.

None of the authors has any conflict of interest regarding the publication of this manuscript.

Illustrations were done by Alon Person, via Adobe Illustrator cc 2019.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Abstract

Immediate breast reconstruction (IBR) rates after mastectomy are increasing. Postmastectomy radiation therapy (PMRT) contouring guidelines for target volumes in the setting of IBR are lacking. Therefore, many patients who have had IBR receive PMRT to target volumes similar to conventional simulator-based whole breast irradiation. The aim of this paper is to describe delineation guidelines for PMRT after implant-based IBR based on a thorough understanding of the surgical procedures, disease stage, patterns of recurrence and radiation techniques. They are based on a consensus endorsed by a global multidisciplinary group of breast cancer experts.

Introduction

Breast cancer is the most common non-skin cancer in women worldwide. The vast majority of patients have non-metastatic disease at diagnosis [1]. The rates of mastectomy with an immediate breast reconstruction (IBR), mainly an implant/prosthesis-based reconstruction (IBR-i), as a surgical treatment for early breast cancer patients are increasing [2, 3].

Indications for postmastectomy radiation therapy (PMRT) are based on tumour-related characteristics and other prognostic risk factors. Lately, the number of patients receiving PMRT [4](Frasier, et al. 2016)(Frasier, et al. 2016)(Frasier, et al. 2016) has increased based on evidence that PMRT for pN1 breast cancer patients treated with mastectomy and axillary dissection reduces recurrences and breast cancer mortality [4-6]. Although some studies have suggested that PMRT in the setting of reconstruction increases the relative rate of complications regardless of the type (implant or autologous) and the timing of reconstruction [7-9], fewer complications and better long-term cosmetic outcome have been reported when an autologous flap-based reconstruction was performed compared to IBR-i in combination with PMRT [7-10]. The IBR-i has ~ 2.64 times higher odds of complications (95% CI 1.77, 3.94, $p < 0.001$) than autologous-flap-based reconstruction. The rates of reconstruction failure in the setting of PMRT at two years was reported to be 18.7% among patients with IBR-i versus 1% in the autologous reconstruction group [10].

Radiation therapy (RT) in the setting of breast reconstruction is challenging. Surgical techniques for breast reconstruction continue to develop with the aim of improving cosmetic outcomes via pre or post-pectoral placement of the implant, or the use of an autologous-flap, lipofilling or synthetic coverage materials in conjunction with the implant [11]. However, little is known about the oncological outcomes associated with these techniques, the impact of RT on cosmetic results,

1
2
3
4 and factors underpinning these outcomes after breast reconstruction and PMRT [2, 7, 9, 12, 13].

5
6
7 In addition, most studies of breast reconstruction and PMRT did not specify the influence of
8
9 radiation techniques and dose-fractionation schedules used or the long-term oncological
10
11 outcomes including patterns of recurrence [12-15].
12
13

14
15 Current PMRT techniques used in the post-IBR setting are still often field-based rather than
16
17 volume-based such that the target volume frequently includes the implant or reconstructed breast
18
19 itself. The use of modern volume-based RT planning may reduce the dose to normal tissue and
20
21 thereby treatment-related toxicity, without compromising target coverage [16].
22
23

24
25 Our multidisciplinary initiative aims to define delineation guidelines for the clinical target
26
27 volume (CTV) for PMRT in the setting of IBR-i and autologous IBR (IBR-a). This manuscript
28
29 focuses on the setting of IBR-i, presenting the consensus guideline aiming to limit the CTV to
30
31 clinically relevant volumes and thereby the risks of RT-related complications.
32
33
34
35
36
37

38 **Methods**

39
40
41 In February 2016 the challenges of PMRT in the setting of IBR were discussed at the Assisi
42
43 Think-Tank Meeting on breast cancer [17]. In addition, development of the DBCG RT Recon
44
45 Trial (ClinicalTrials.gov NCT03730922), a randomised study of the Danish Breast Cancer Group
46
47 (DBCG) for patients who require PMRT and plan to have IBR-i as a first step of a delayed-
48
49 immediate breast reconstruction necessitated development of guidelines for target volume
50
51 delineation. An international group of breast cancer experts (BVO, PP, OKP, LB, CC, IM)
52
53 developed a delineation guideline including CTV definition for the DBCG trial, and evaluated its
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 feasibility and dosimetric considerations using treatment planning CT scans of two patients who
5
6 had an IBR-i [18].
7
8

9
10 In November 2017 a broader international multidisciplinary group of breast cancer experts
11 including breast surgeons, plastic surgeons, radiation oncologists, and clinical oncologists
12 (authors list) was invited to participate in the consensus guidelines development via the
13
14 following steps:
15
16
17
18

19
20 1) Between January and March 2017 the current practices for IBR-PMRT of the expert group
21 were assessed via a multiple-choice web-questionnaire of 6 questions (Table 1).
22
23

24
25 2) The expert group participated in a European Society of Radiation & Oncology (ESTRO)'s
26 FALCON platform-based [19] CTV contouring exercise using four representative cases which
27 comprised two IBR-i cases and two-IBR-a cases. The writers of the DBCG RT Recon Trial
28 guidelines visually compared and discussed the CTVs contoured separately for the group
29 involved in development of the DBCG delineation guidelines and the group of experts who were
30 not involved. This was also done separately for the breast- and plastic surgeons and oncologists.
31
32 Email correspondences among the participants regarding the challenges in contouring the CTVs
33 were reviewed and discussed.
34
35

36
37 3) The project was presented by PP at the 11th European Breast Cancer Conference (EBCC11) in
38 March 2018, and a panel discussion was conducted about potential factors associated with
39
40 cosmetic outcomes in the setting of IBR and PMRT. This panel included three more
41
42 representatives from our breast cancer expert team (FM, MJC, OKP).
43
44

45
46 4) Sixteen expert team members met in a closed session at ESTRO 37 in April 2018 to discuss
47
48 outcomes of the survey and delineation exercise; challenges of CTV delineation for IBR-i versus
49
50
51
52
53
54
55
56
57
58
59
60
61
62

1
2
3
4 IBR-a; additional data required to complete the consensus guidelines especially for IBR-a;
5
6 modification of the guidelines based on surgical data, disease stage, site of recurrence; and
7
8 current practices.
9

10
11
12 5) An open panel discussion chaired by BVO was held at ESTRO 37 in April 2018. The project
13
14 was presented by PP [20] and OKP [21]. Input from the audience was taken into consideration in
15
16 the consensus guidelines development.
17

18
19
20 6) At all times, the expert group members communicated via email to resolve outstanding issues
21
22 in guidelines development. The core group (BVO, PP, OKP) conducted teleconferences and
23
24 face-to-face meetings to finalize the guidelines.
25
26

27
28 7) The draft manuscript was written by the core group (BVO, PP, OKP), and reviewed and
29
30 approved by all authors. The other expert group members are acknowledged in the manuscript.
31
32

33 34 35 36 **Results**

37 38 39 *Group pre-work based on web-questionnaire*

40
41
42 According to the results of web-questionnaire (Table 1), most participants agreed that target
43
44 volume delineation guidelines for IBR according to the surgical procedure can be applied in
45
46 clinical practice once they are made available.
47
48

49 50 51 52 53 *Results of delineation exercise*

54
55
56 The visual comparison of the CTV contours between the different groups of contributors to the
57
58 guideline is illustrated in Figure 1. A high consistency was observed among the writers of the
59
60

1
2
3
4 DBCG RT Recon Trial, half of the other radiation oncologists and one surgeon. While the other
5
6 surgeon contoured a much smaller CTV, the other half of the radiation oncologists included the
7
8 entire chest wall with the implant, similar to a conventional simulator-based treatment set up.
9

10
11
12
13
14
15 *Recommendations on target volume delineation for chest wall*
16

17
18 A sound understanding of the breast's anatomy, regional lymphatics drainage patterns, disease
19
20 stage, and procedures of breast surgery and IBR is essential to guide delineation of the
21
22 CTVp_chest wall (i.e., p – primary). Detailed surgical and pathological reports are required. We
23
24 recommend marking of scars and palpable/visible anatomical and surgical effects such as the
25
26 borders of the surgical resection of subcutaneous, breast and fatty tissue.
27
28
29

30
31 Although the skin is not part of the CTV, except in patients with a T4b, T4c and T4d breast
32
33 cancer, the subcutaneous lymphatic plexus clearly is. During a total mastectomy the skin is
34
35 pulled together and sutured, thereby reducing the size of the CTVp_chest wall compared to a
36
37 CTVp_breast. The surface-reducing effect of mastectomy as described above is not the case
38
39 when skin-sparing (with removal of nipple-areolar complex) or nipple-sparing (with preservation
40
41 of skin and nipple-areolar complex) mastectomy is performed. These surgical approaches have
42
43 gained popularity as initial reports have not shown a higher local recurrence rate than patients
44
45 treated with skin-ablating mastectomy [22]. However, as more skin is preserved, it is likely that
46
47 there will be more residual draining lymphatics and mammary glandular tissue [23], potentially
48
49 resulting in an increase in local recurrence risk [23-25]. Moreover, uncertainty in defining the
50
51 residual glandular tissue remains due to the limited data available [24, 26, 27]. The location of
52
53 the residual glandular tissue varies in individual patients and depending on surgical procedure
54
55 performed (with/without skin or nipple sparing). In most patients, it is found laterally in the
56
57
58
59
60
61
62
63
64
65

1
2
3
4 “axillary-tail” and in up to 22% of cases in the upper inner quadrant [23]. We strongly
5
6 recommend that the borders of residual skin be determined in conjunction with the surgeon and
7
8 marked before planning CT scanning. The CT scans should also be reviewed for residual tissue
9
10 that is not evident on physical examination.
11
12
13
14
15
16

17 *Understanding the mammary lymphatic drainage pattern*

18
19
20 The lymphatics from the mammary region drain via the dermal plexus located within the
21
22 subcutaneous tissues (Figure 2). The glandular tissue over the dorsal fascia of the breast is not
23
24 connected to the major pectoral muscle, and hence, in the absence of tumour invasion the muscle
25
26 is not part of the CTVp_chest wall. About three quarters of the lymphatics drains to the axillary
27
28 nodes. The lymphatics may also drain into a connection along the borders of the glandular tissue
29
30 and then around the edge of the major pectoral muscle into the interpectoral (Rotter’s) nodes
31
32 (Figure 2) or through or between the pectoral muscles directly to the apical axillary nodes.
33
34
35 Lymphatics may finally also drain alongside the penetrating blood vessels through the medial
36
37 side of the major pectoral muscle into the internal mammary nodes. Thus, the deep lymphatic
38
39 plexus (Figure 2, level 2-4) is part of the target volume in patients with more advanced breast
40
41 cancer who should also be considered for internal mammary lymph node irradiation [28-30].
42
43
44 Target volumes for elective nodal irradiation should be contoured according to the ESTRO
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

66 *Understanding the surgical procedure of IBR-i:*

1
2
3
4 The mastectomy procedure may vary according to oncological and aesthetic requirements. In
5
6 general, the mammary gland is dissected from the skin envelope along the subcutaneous
7
8 (Scarpa's fascia) plane. The nipple areolar complex may or may not be preserved (see below).
9

10
11 The gland is dissected off the pectoral muscle in the plane between the retro-mammary and pre-
12
13 pectoral fascia, preserving the fascia if oncologically appropriate.
14

15
16 The implant (tissue expander or permanent implant) may be positioned *pre* or *post* to the major
17
18 pectoral muscle:
19

- 20
21
22 1) *Posterior (dorsal)* to the major pectoral muscle (retro-pectoral position). Additional
23
24 materials e.g. de-epithelialized dermal flap, synthetic mesh or a bio-mesh of animal or
25
26 human tissues (acellular dermal matrix - ADM) are most often used to provide complete
27
28 coverage of the implant caudally of the pectoral muscle and to achieve the preferred
29
30 breast shape (Figure 3A, B).
31
- 32
33 2) *Anterior (ventral)* to the major pectoral muscle (pre-pectoral) directly into the skin
34
35 pocket. The implant is secured in position with a mesh covering the largest part of the
36
37 superficial surface of the implant (Figure 3C) [33, 34].
38
39
40

41
42 After mastectomy, the CTVp_chest wall includes the residual subcutaneous glandular tissue and
43
44 the subcutaneous lymphatics. The major pectoral muscle serves as the anatomical *dorsal* border
45
46 for mastectomy. The muscle is typically described in anatomy textbooks as a thick fan-shaped
47
48 muscle, originating from the medial half of the clavicle and *ventral* surface of the sternum as
49
50 well as the cartilage of the 6th or 7th rib, and inserting into the bicipital groove and deltoid
51
52 tuberosity of the humerus. Therefore, former CTVp_chest wall usually includes the levels from
53
54 2nd to 6th rib in *craniocaudal* direction. However, according to the ESTRO guideline [31, 32],
55
56 observing mastectomy procedures for the purpose of developing the current guidelines and
57
58
59
60
61

1
2
3
4 evaluating RT-planning CT-scans, anatomical aspects such as size (extent and thickness) of the
5
6 major pectoral muscle and position of the breast varies among women, dependent on age, body
7
8 mass index, patient's fitness, etc. Therefore, in general most of the breast glandular tissue is
9
10 positioned ventral to the major pectoral muscle, whilst a smaller more lateral part of glandular
11
12 tissue is located ventral to the anterior serratus muscle and more caudally ventral to the ribs and
13
14 intercostal muscles and in some patients, up to the ventral part of the external oblique abdominal
15
16 muscle (Figure 4A, B). Consequently, per ESTRO recommendation for CTVp_chest wall
17
18 delineation, the *cranio-caudal borders* should be defined by careful clinical examination of the
19
20 patient with positioning of skin markers for the planning-CT (e.g., scars) and taking into account
21
22 the position of the contralateral breast. It is not advisable to use the latter as a mere mirror
23
24 because during mastectomy, both parts of the CTV are approximated, thereby reducing the
25
26 surface of the target volume compared to the intact breast [31, 32]. The *medial* and *lateral*
27
28 borders should be per ESTRO recommendations for chest wall delineation [31, 32].
29
30
31
32
33
34
35

36 Importantly, approximately 5-10% of the glandular tissue is retained after conventional total
37
38 mastectomy [23]. It is essential to include residual glandular tissue within the CTVp_chest wall.
39
40
41
42
43

44 *CTVp_chest wall after IBR general*

45
46

47
48 Our recommendations for the CTVp_chest wall are based on the observation that most of the
49
50 local recurrences after mastectomy occur at the level of the skin and subcutaneous tissue (range,
51
52 72-100%), where most of the residual glandular tissues and draining lymphatics are found [35,
53
54 36]. The second most common site of recurrence is within the pectoral muscle, especially nearby
55
56 the primary tumour site (0-28%) [35, 36]. In general, the CTVp_chest wall is positioned *ventral*
57
58 (anterior) to the major pectoral muscle. In case of muscle invasion, local inclusion of that part of
59
60
61
62
63
64
65

1
2
3
4 the pectoral muscle is advised, and in case of rib cage invasion the ribs/intercostal muscles
5
6 should also be focally included in the CTV [32]. As IBR is generally not advised in these
7
8 patients, the *dorsal* (posterior) border of the CTV in most cases will be on the *ventral* side of the
9
10 major pectoral muscle or the ribs and intercostal muscles where no pectoral muscle was present
11
12 before surgery [32]. In the case of a retro-pectoral implant, the surgeon generally detaches the
13
14 caudal and medial insertion of the major pectoral muscle. If thereby the original position of the
15
16 pectoral muscle cannot be clearly identified on the planning CT scan, the *dorsal* CTV border
17
18 may be extended locally over the *ventral* side of the ribs [36, 37]. It is therefore strongly advised
19
20 that the surgeon places clips to assist in the location of the primary tumour site and in the case of
21
22 a retro-pectoral implant also of the pre-surgical insertion of the major pectoral muscle on the
23
24 ribs. Delineation should preferably be undertaken in conjunction with the surgeon to
25
26 individualise the CTVp_chest wall according to the primary tumour site and degree of tumour
27
28 extension.
29
30
31
32
33
34
35
36
37
38

39 *CTVp_chest wall after IBR using post-pectoral implant (Figure 3A, B)*

40

41
42 If the dorsal fascia of the breast is not involved by cancer, the CTVp_chest wall for PMRT does
43
44 not include the deep lymphatic plexus and therefore only includes the rim of tissue ventral to the
45
46 major pectoral muscle and the implant, except at the medial, lateral and caudal borders where it
47
48 may extend to the *ventral* side of the chest wall where it is not covered by the pre-surgical
49
50 extension of the major pectoral muscle. Thus, the implant can be largely excluded from the
51
52 CTVp_chest wall, while the parts of the chest wall surrounding the pectoral muscle around
53
54 which the lymphatics flow should still be included (Figure 4A, B). As the pectoral muscle
55
56 overlying the implant is very thin in some women, the muscle would inevitably be included at
57
58
59
60
61
62
63
64
65

1
2
3
4 least partially in the CTV, meaning that the dorsal margin of the CTV would be at the ventral
5
6 side of the implant.
7
8

9
10 For patients with adverse factors and/or where the tumour was localised in areas within the
11 breast close to the dorsal fascia that was not covered by the major pectoral muscle (mainly
12 caudally located tumours that are often located adjacent to the intercostal muscles and ribs), only
13
14 separated by the dorsal breast fascia, we recommend to delineate the tissue between the chest
15 wall and the implant caudal from the pre-surgical position of the major pectoral muscle (ideally
16 marked by surgical clips), which can be done as a separate dorsal CTV (Table 2; Figure 4B).
17
18
19
20
21
22
23
24
25
26

27 *CTVp_chest wall after IBR with pre-pectoral implant*

28
29

30 After IBR-i using a pre-pectoral positioned implant, the CTVp_chest wall is composed of 2 parts
31 as the pre-pectoral volume is divided into 2 parts by the implant (Figure 3C):
32
33
34
35

- 36 1) the ventral part between the skin and the implant, containing the subcutaneous lymphatic
37 plexus and eventual residual glandular tissue (Figure 4C, red contour);
38
39
- 40 2) the dorsal part between the implant and the pectoral muscle/chest wall, containing
41 eventual residual glandular tissue (Figure 4C, blue contour): only to be included in case
42 of the presence of adverse tumour factors (Table 2).
43
44
45
46
47
48
49
50
51

52 *Volumes to be delineated: summary*

53
54

55 The implant and the contralateral breast should be delineated using a planning-CT (Table 3). The
56 transplanted tissues (skin; fat; muscle) and synthetic materials (implant, tissue expander, ADM)
57 are not part of the CTV. They could be contoured as organs at risk (OAR), without the aim to
58
59
60
61

1
2
3
4 compromising the CTVp_chest wall coverage. Other OARs that should be delineated for
5
6 treatment planning purposes include heart, lungs, liver, thyroid and, in case of axillary lymph
7
8 node irradiation with a regional boost, the brachial plexus.
9

15 **Discussion**

16
17
18 Consensus-based guidelines on radiation target volume definition in patients with breast cancer
19
20 treated with mastectomy and IBR are lacking. Most publications reporting on PMRT after
21
22 immediate or other breast reconstruction do not provide sufficient details on target volume
23
24 delineation and RT planning. The current paper provides a detailed delineation guideline for
25
26 PMRT after IBR-i endorsed by a global multidisciplinary group of breast cancer experts.
27
28

29
30 It is recommended that the guidelines be considered in the context of complete information about
31
32 loco-regional disease staging (including staging pre and post primary systemic therapy if
33
34 applicable); individual anatomical variations (e.g. chest wall thickness); location of potential
35
36 residual glandular tissue in discussion with the surgical team; evaluation of the contralateral
37
38 intact breast and the pectoral muscles on planning CT; and the surgical procedures.
39
40

41
42
43 Multidisciplinary collaboration is essential; breast surgeons are important partners in contouring
44
45 the appropriate CTVp_chest wall. Moreover, patients who are planned to have a mastectomy and
46
47 IBR-i should be pre-operatively evaluated by both the surgeons and radiation oncologists or
48
49 alternatively, discussed at multidisciplinary tumour board meetings.
50
51

52
53
54 Selected patients with LABC may be considered for IBR. In these cases, the CTV, based on the
55
56 general guidelines and discussions in a multidisciplinary team conference, should be if required
57
58 carefully individually adapted per case, according to the high-risk areas for remaining subclinical
59
60

1
2
3
4 tumour deposits. In any case that the tumour staging is unknown/unclear, we recommend to
5
6 irradiate after IBR-i in a manner similar to conventional simulator-based RT approaches for
7
8 preserved breast irradiation, thereby including the entire mastectomy site including the implant.
9

10
11 If the skin is not part of the target volume, the *ventral* limit is conventionally 5 mm deep to the
12
13 skin surface to include the subcutaneous lymphatics of the breast. However, this may not be
14
15 possible due to the surgical procedure and the stretching of the remaining skin over the implant
16
17 resulting in a thin rim of skin envelop, making it impossible to crop the CTVp_chest wall to 5
18
19 mm below the skin surface. There is no high-level evidence to guide the use of bolus material to
20
21 increase the skin dose in PMRT after IBR. In preparation of the DBCG RT Recon trial protocol,
22
23 planning of two test cases using a tangential, forward planned field-in-field technique showed
24
25 that there was 100% skin dose over most of the reconstructed breasts with 6 MV photons without
26
27 a bolus, except medially and laterally corresponding to entry and exit of the beams. Due to the
28
29 potentially superficial location of subcutaneous lymphatics, we do not recommend cropping of
30
31 the CTVp_chest wall 5 mm from the skin surface but, depending on the software for dose
32
33 calculation used, including the skin surface in the CTVp_chest wall without routinely using
34
35 additional bolus to optimise inverse treatment plan calculations and DVH-evaluation of the dose
36
37 distribution.
38
39
40
41
42
43
44

45
46 After a mastectomy with IBR, identification of the tumour bed is complex and challenging due to
47
48 manipulation of the tissue during reconstruction. Therefore, we do not recommend the use of a
49
50 “tumour bed” boost, unless the surgeon has placed clips to mark anticipated and subsequently
51
52 confirmed involved resection margins that cannot be removed surgically.
53
54
55
56

57 The current guidelines are intended for target volume delineation after IBR-i. Development of
58
59 target volume delineation guidelines after IBR-a is in progress and is more complicated due to
60
61

1
2
3
4 the range of surgical procedures. This paper does not support one breast reconstruction procedure
5
6 over the other.
7

8
9
10 By using volume-based RT, we aim to reduce potential complications by tailoring the target
11
12 volume to tissues at risk for recurrence. It is necessary that patients treated according to the
13
14 current guidelines be carefully monitored in terms of long-term oncological safety, treatment
15
16 toxicity and cosmetic outcome. Hence, we support initiatives of prospective databases, such as
17
18 the INSPIRE prospective cohort study and the Mastectomy Reconstruction Outcome Consortium
19
20 (MROC) [10] to evaluate patient outcomes after mastectomy and reconstruction. We also
21
22 encourage centres to participate in clinical trials such as the DBCG RT Recon Trial or the
23
24 Primary Radiotherapy And DIEP flAp Reconstruction Trial (PRADA) (NCT02771938)
25
26 (<https://clinicaltrials.gov/ct2/show/NCT02771938>), and contribute data to the prospective cohort
27
28 study coordinated by the authors of the current guidelines (NCT03730922).
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48

49 **References**

50
51
52 [1] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics
53
54 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185
55
56 countries. CA: a cancer journal for clinicians. 2018.
57
58
59
60
61

- 1
2
3
4 [2] Agarwal S, Kidwell KM, Farberg A, Kozlow JH, Chung KC, Momoh AO. Immediate
5
6 Reconstruction of the Radiated Breast: Recent Trends Contrary to Traditional Standards. *Annals*
7
8 of surgical oncology. 2015;22:2551-9.
9
10
11 [3] Kummerow KL, Du L, Penson DF, Shyr Y, Hooks MA. Nationwide trends in mastectomy for
12
13 early-stage breast cancer. *JAMA Surg.* 2015;150:9-16.
14
15
16 [4] Frasier LL, Holden S, Holden T, Schumacher JR, Levenson G, Anderson B, et al. Temporal
17
18 Trends in Postmastectomy Radiation Therapy and Breast Reconstruction Associated With
19
20 Changes in National Comprehensive Cancer Network Guidelines. *JAMA Oncol.* 2016;2:95-101.
21
22
23 [5] Ebtctg, McGale P, Taylor C, Correa C, Cutter D, Duane F, et al. Effect of radiotherapy after
24
25 mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality:
26
27 meta-analysis of individual patient data for 8135 women in 22 randomised trials. *Lancet.*
28
29 2014;383:2127-35.
30
31
32 [6] Marks LB, Kaidar-Person O, Poortmans P. Regarding Current Recommendations for
33
34 Postmastectomy Radiation Therapy in Patients With One to Three Positive Axillary Lymph
35
36 Nodes. *Journal of clinical oncology : official journal of the American Society of Clinical*
37
38 *Oncology.* 2017;35:1256-8.
39
40
41 [7] Momoh AO, Ahmed R, Kelley BP, Aliu O, Kidwell KM, Kozlow JH, et al. A systematic
42
43 review of complications of implant-based breast reconstruction with prereconstruction and
44
45 postreconstruction radiotherapy. *Annals of surgical oncology.* 2014;21:118-24.
46
47
48 [8] Kelley BP, Ahmed R, Kidwell KM, Kozlow JH, Chung KC, Momoh AO. A systematic
49
50 review of morbidity associated with autologous breast reconstruction before and after exposure
51
52 to radiotherapy: are current practices ideal? *Annals of surgical oncology.* 2014;21:1732-8.
53
54
55
56
57
58
59
60
61
62
63
64
65

- 1
2
3
4 [9] Jagsi R, Jiang J, Momoh AO, Alderman A, Giordano SH, Buchholz TA, et al. Complications
5
6 After Mastectomy and Immediate Breast Reconstruction for Breast Cancer: A Claims-Based
7
8 Analysis. *Ann Surg.* 2016;263:219-27.
9
10
11 [10] Jagsi R, Momoh AO, Qi J, Hamill JB, Billig J, Kim HM, et al. Impact of Radiotherapy on
12
13 Complications and Patient-Reported Outcomes After Breast Reconstruction. *J Natl Cancer Inst.*
14
15 2018;110.
16
17
18 [11] Cook LJ, Kovacs T. Novel devices for implant-based breast reconstruction: is the use of
19
20 meshes to support the lower pole justified in terms of benefits? A review of the evidence.
21
22 *Ecancermedalscience.* 2018;12:796.
23
24
25 [12] Lohmander F, Lagergren J, Roy PG, Johansson H, Brandberg Y, Eriksen C, et al. Implant
26
27 Based Breast Reconstruction With Acellular Dermal Matrix: Safety Data From an Open-label,
28
29 Multicenter, Randomized, Controlled Trial in the Setting of Breast Cancer Treatment. *Ann Surg.*
30
31 2018.
32
33
34 [13] Krastev T, van Turnhout A, Vriens E, Smits L, van der Hulst R. Long-term Follow-up of
35
36 Autologous Fat Transfer vs Conventional Breast Reconstruction and Association With Cancer
37
38 Relapse in Patients With Breast Cancer. *JAMA Surg.* 2018.
39
40
41 [14] Poppe MM, Agarwal JP. Breast Reconstruction With Postmastectomy Radiation: Choices
42
43 and Tradeoffs. *Journal of clinical oncology : official journal of the American Society of Clinical*
44
45 *Oncology.* 2017;JCO2017727388.
46
47
48 [15] Ho A, Cordeiro P, Disa J, Mehrara B, Wright J, Van Zee KJ, et al. Long-term outcomes in
49
50 breast cancer patients undergoing immediate 2-stage expander/implant reconstruction and
51
52 postmastectomy radiation. *Cancer.* 2012;118:2552-9.
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 [16] Kaidar-Person O, Jones EL, Zagar TM. Team Work: Mastectomy, Reconstruction, and
5
6 Radiation. *Plast Reconstr Surg Glob Open*. 2017;5:e1385.
7
8

9
10 [17] Aristei C, Kaidar-Person O, Arenas M, Coles C, Offersen BV, Bourgier C, et al. The 2016
11
12 Assisi Think Tank Meeting on breast cancer: white paper. *Breast Cancer Res Treat*.
13
14 2016;160:211-21.
15
16

17 [18] H.D. Nissen ESY, K. Andersen, L. Boersma, K. Boye, R. Canter, C. Coles, E. Costa, S.
18
19 Daniel, S. Ho, I. Jensen, E.L. PO-0918: Consensus on target volume delineation and treatment
20
21 planning strategy for the DBCG RT Recon trial. *Radiotherapy and oncology : journal of the*
22
23 *European Society for Therapeutic Radiology and Oncology*. 2018;127:S492-S4.
24
25
26

27 [19] Eriksen JG, Salembier C, Rivera S, De Bari B, Berger D, Mantello G, et al. Four years with
28
29 FALCON - an ESTRO educational project: achievements and perspectives. *Radiotherapy and*
30
31 *oncology : journal of the European Society for Therapeutic Radiology and Oncology*.
32
33 2014;112:145-9.
34
35
36

37 [20] Poortmans P. SP-0017: Breast reconstruction: a past or present challenge for the radiation
38
39 oncologist? *Radiotherapy and oncology : journal of the European Society for Therapeutic*
40
41 *Radiology and Oncology*. 2018;127:s6.
42
43
44

45 [21] Kaidar-Person O. SP-0019: Brother and sister: guidelines for bringing breast reconstruction
46
47 and radiation therapy together. *Radiotherapy and oncology : journal of the European Society for*
48
49 *Therapeutic Radiology and Oncology*. 2018;127:S6-S7.
50
51
52

53 [22] Carlson GW, Bostwick J, 3rd, Styblo TM, Moore B, Bried JT, Murray DR, et al. Skin-
54
55 sparing mastectomy. *Oncologic and reconstructive considerations*. *Ann Surg*. 1997;225:570-5;
56
57 discussion 5-8.
58
59
60

- 1
2
3
4 [23] Woitek R, Pfeiler G, Farr A, Kapetas P, Furtner J, Bernathova M, et al. MRI-based
5
6 quantification of residual fibroglandular tissue of the breast after conservative mastectomies. Eur
7
8 J Radiol. 2018;104:1-7.
9
- 10
11 [24] Carlson GW, Styblo TM, Lyles RH, Bostwick J, Murray DR, Staley CA, et al. Local
12
13 recurrence after skin-sparing mastectomy: tumor biology or surgical conservatism? Annals of
14
15 surgical oncology. 2003;10:108-12.
16
17
18
19 [25] Meretoja TJ, Rasia S, von Smitten KA, Asko-Seljavaara SL, Kuokkanen HO, Jahkola TA.
20
21 Late results of skin-sparing mastectomy followed by immediate breast reconstruction. Br J Surg.
22
23 2007;94:1220-5.
24
25
26
27 [26] Marta GN, Poortmans PM, Buchholz TA, Hijal T. Postoperative Radiation Therapy after
28
29 Nipple-Sparing or Skin-Sparing Mastectomy: A Survey of European, North American, and
30
31 South American Practices. Breast J. 2017;23:26-33.
32
33
34
35 [27] Marta GN, Poortmans P, de Barros AC, Filassi JR, Freitas Junior R, Audisio RA, et al.
36
37 Multidisciplinary international survey of post-operative radiation therapy practices after nipple-
38
39 sparing or skin-sparing mastectomy. Eur J Surg Oncol. 2017;43:2036-43.
40
41
42
43 [28] Poortmans PM, Collette S, Kirkove C, Van Limbergen E, Budach V, Struikmans H, et al.
44
45 Internal Mammary and Medial Supraclavicular Irradiation in Breast Cancer. N Engl J Med.
46
47 2015;373:317-27.
48
49
50
51 [29] Thorsen LB, Offersen BV, Dano H, Berg M, Jensen I, Pedersen AN, et al. DBCG-IMN: A
52
53 Population-Based Cohort Study on the Effect of Internal Mammary Node Irradiation in Early
54
55 Node-Positive Breast Cancer. Journal of clinical oncology : official journal of the American
56
57 Society of Clinical Oncology. 2016;34:314-20.
58
59
60
61
62
63
64
65

1
2
3
4 [30] Whelan TJ, Olivotto IA, Parulekar WR, Ackerman I, Chua BH, Nabid A, et al. Regional
5
6 Nodal Irradiation in Early-Stage Breast Cancer. *N Engl J Med*. 2015;373:307-16.
7

8
9
10 [31] Offersen BV, Boersma LJ, Kirkove C, Hol S, Aznar MC, Biete Sola A, et al. ESTRO
11
12 consensus guideline on target volume delineation for elective radiation therapy of early stage
13
14 breast cancer. *Radiotherapy and oncology : journal of the European Society for Therapeutic*
15
16 *Radiology and Oncology*. 2015;114:3-10.
17

18
19
20 [32] Offersen BV, Boersma LJ, Kirkove C, Hol S, Aznar MC, Sola AB, et al. ESTRO consensus
21
22 guideline on target volume delineation for elective radiation therapy of early stage breast cancer,
23
24 version 1.1. *Radiotherapy and oncology : journal of the European Society for Therapeutic*
25
26 *Radiology and Oncology*. 2016;118:205-8.
27

28
29
30 [33] Highton L, Johnson R, Kirwan C, Murphy J. Prepectoral Implant-Based Breast
31
32 Reconstruction. *Plast Reconstr Surg Glob Open*. 2017;5:e1488.
33

34
35 [34] Casella D, Di Taranto G, Marcasciano M, Sordi S, Kothari A, Kovacs T, et al. Evaluation of
36
37 prepectoral implant placement and complete coverage with TiLoop(R) Bra mesh for breast
38
39 reconstruction: a prospective study on long-term and patient reported BREAST-Q outcomes.
40
41 *Plast Reconstr Surg*. 2018.
42

43
44
45 [35] Vargo JA, Beriwal S. RTOG Chest Wall Contouring Guidelines for Post-Mastectomy
46
47 Radiation Therapy: Is It Evidence-Based? *International journal of radiation oncology, biology,*
48
49 *physics*. 2015;93:266-7.
50

51
52
53 [36] Vargo JA, Beriwal S. In reply to Chang et al.: Contouring guidelines for post-mastectomy
54
55 radiotherapy a cry for international consensus. *Radiotherapy and oncology : journal of the*
56
57 *European Society for Therapeutic Radiology and Oncology*. 2017;123:483-4.
58
59
60
61

1
2
3
4 [37] Chang JS, Byun HK, Kim JW, Kim KH, Lee J, Cho Y, et al. Three-dimensional analysis of
5
6 patterns of locoregional recurrence after treatment in breast cancer patients: Validation of the
7
8 ESTRO consensus guideline on target volume. Radiotherapy and oncology : journal of the
9
10 European Society for Therapeutic Radiology and Oncology. 2017;122:24-9.
11
12
13

14 **DISCLAIMER**

15
16 *ESTRO cannot endorse all statements or opinions made on the guidelines. Regardless of the*
17 *vast professional knowledge and scientific expertise in the field of radiation oncology that*
18 *ESTRO possesses, the Society cannot inspect all information to determine the truthfulness,*
19 *accuracy, reliability, completeness or relevancy thereof. Under no circumstances will ESTRO*
20 *be held liable for any decision taken or acted upon as a result of reliance on the content of the*
21 *guidelines.*
22
23

24 *The component information of the guidelines is not intended or implied to be a substitute for*
25 *professional medical advice or medical care. The advice of a medical professional should*
26 *always be sought prior to commencing any form of medical treatment. To this end, all*
27 *component information contained within the guidelines is done so for solely educational and*
28 *scientific purposes. ESTRO and all of its staff, agents and members disclaim any and all*
29 *warranties and representations with regards to the information contained on the guidelines.*
30 *This includes any implied warranties and conditions that may be derived from the*
31 *aforementioned guidelines.*
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Highlights

- We present multidisciplinary consensus-based target volume definitions for chest wall irradiation after mastectomy with immediate breast reconstruction.
- Practical guidelines for target volume contouring in case of a retro-pectoral as well as a pre-pectoral implant are now available.
- These guidelines allow anatomically risk-adapted radiation therapy planning, avoiding the inclusion of non-target tissue like the implant.

Conflict of interest statement

The authors declare that they have no competing interests.
None of the authors has any financial and personal relationships with other people or organisations that could inappropriately influence (bias) of this work.

Table 1: Pework web-questionnaire

| Question | Answers (# of participants) |
|---|--|
| In your daily practice, in case of IBR irradiation do you delineate target volume of chest wall/reconstructed breast? | a. "yes", in most cases. Target volumes are used for treatment set-up. (18) b. "yes", in most cases, after virtual simulation to enable dose homogenization. (2) c. "no", in most cases we irradiate the volume of the whole reconstruction breast (similar volumes like virtually simulated RT for breast in place). (8) |
| In the affirmative, do you delineate the clinical target volume according to the surgical procedure? | a. "yes", in most cases. (15) b. "no", the target volume is in general very similar. (9) c. "no", the target volume is similar like for the breast in place. (1) |
| In the affirmative, in which case do you find it easier to delineate the clinical target volume? | a. In cases of IBR-i. (17) b. In both IBR-i and IBR-a. (6) c. None. (3) d. In cases of IBR-a. (0) |
| What would be helpful to define the clinical target volume in cases of IBR? | a. Detailed surgical and pathological report. (5) b. Delineating with the assistance of a breast surgeon. (1) c. Extensive marking of scars and palpable/visible surgical effects. (0) d. At least 2 of the above. (12) e. a+b+c (8) f. The clinical target volume should be the IBR (similar to virtual RT for breast in place) irrespective of the type of surgery performed. (3) |
| Can volume delineation guidelines for IBR according to the surgical procedure be applied in the clinical practice? | a. "yes". (23) b. "no", until data from clinical trials is available. (4) c. "no", surgical procedures change significantly which might compromise oncological outcomes. (1) |
| How many PMRT IBR cases you treat a year? | a. < 10 (7) b. 10-20 (7) c. > 20 (14) |

RT – Radiation therapy; PMRT- Postmastectomy radiation therapy ; IBR-immediate breast reconstruction; IBR-i – implant-based; IBR-a – autologous tissue based.

Table 2: Indications for including a volume posterior to the implant in the CTVp_chestwall:

Partial inclusion in post-pectoral implant positioning: in case of the presence of adverse factors and/or if the tumour was localised in areas within the breast close to the dorsal fascia that was not covered by the initial position of the major pectoral muscle: separate volume (blue volume in fig 4B)

Complete inclusion in pre-pectoral implant positioning: in case of the presence of adverse factors (blue in fig 4C)

Adverse prognostic tumour characteristics include:

- Large primary breast cancer (pT3) treated by mastectomy and IBR-i
- Locally advanced breast cancer (LABC) with non-pathological complete response to primary systemic therapy
- Invasion of the major pectoral muscle and/or the chest wall

Table 3: ESTRO delineation guidelines for the CTV in case of implant-based immediate breast reconstruction*. The ventral or superficial part of the CTVp_chestwall includes the space between the skin and the superficial sides of the pectoral muscles and the implant where not covered by muscle. The dorsal or deep part of the CTVp_chestwall is the virtual space between the dorsal side of the implant and the pectoral muscles or ribs and intercostal muscles where no muscle is present. While the ventral part is always part of the CTV, the dorsal part is only included depending on anatomical and tumour-related factors that are listed in table 2.

| Border per region | CTV Retro-pectoral implant: | CTV Pre-pectoral implant |
|-------------------|--|--|
| Cranial | Guided by palpable/visible signs, planning CT; if appropriate guided by the contralateral breast; maximally up to the caudal edge of the sterno-clavicular joint | Guided by palpable/visible signs, planning CT; if appropriate guided by the contralateral breast; maximally up to the caudal edge of the sterno-clavicular joint |
| Caudal | Guided by palpable/visible signs; if appropriate guided by the contralateral breast | Guided by palpable/visible signs; if appropriate guided by the contralateral breast |
| Ventral | 1. Ventral part: if possible, up to 3-5 mm under the skin surface; 2. Dorsal part caudal from original insertion of pectoral muscle: the dorsal side of the implant. | 1) Ventral part: if possible up to 3-5 mm under the skin surface; 2) Dorsal part: the dorsal side of the implant. |
| Dorsal | 1. Ventral part: major pectoral muscle or implant where no muscle; 2. Dorsal part caudal from original insertion of pectoral muscle: ribs and intercostal muscles. ** consider including the superficial part of the pectoral muscle if it is thin or in case of local invasion. | 1) Ventral part: ventral side of the implant. 1) Dorsal part: ventral side of the pectoral muscles or ribs and intercostal muscles where no muscle is present. ** consider including the superficial part of the pectoral muscle in case of local invasion |
| Medial | Guided by palpable/visible signs; if appropriate guided by the contralateral breast. Lateral to the medial perforating mammary vessels. | Guided by palpable/visible signs; if appropriate guided by the contralateral breast. Lateral to the medial perforating mammary vessels. |
| Lateral | Guided by palpable/visible signs; if appropriate guided by the contralateral breast. Usually ventral to the mid-axillary line (important, location of most residual glandular tissue). Ventral to the lateral thoracic artery. | Guided by palpable/visible signs; if appropriate guided by the contralateral breast. Usually ventral to the mid-axillary line (important, location of most residual glandular tissue). Ventral to the lateral thoracic artery. |

*Some of the CTV borders are as previously published in ESTRO guidelines on target volume delineation for elective radiation therapy of early stage breast cancer [21].





Figure 1: CTV contouring of case with immediate breast reconstruction left using an implant. A: by writers of guideline of DBCG RT Recon Trial (n=5); B: by other radiation oncologists (n=18); C: by breast cancer surgeons (n=2).


Figure



Alon Person

Figure 2: Lymphatic draining pattern from the mammary region via the dermal plexus located within the subcutaneous tissues.

Figure



Alon Person

Figure 3: Implant positioning. A: retropectoral with full coverage by the pectoral muscle; B: retropectoral with partial coverage by the pectoral muscle and supportive material in the lower part; C: prepectoral with full coverage by supportive material.




Figure 4A: CTVp_chestwall with only a ventral part (red) in cases for whom only the subcutaneous lymphatic plexus should be irradiated. Pectoral muscles (yellow) and implant (green).




Figure 4B: CTVp_chestwall with a ventral (red) and dorsal (blue) part in cases for whom the subcutaneous lymphatic plexus should be irradiated as well as the part of the chest wall that was initially not covered by the pectoral muscles (yellow). Retropectoral implant (green).




Figure 4C: CTVp_chestwall with a ventral (red) and dorsal (blue) part in cases with a prepectoral implant (green). Pectoral muscles (yellow).